Table 4 Univariate and multivariate analyses of clinical determinants and toxicities

From: Toxicity associated with capecitabine plus oxaliplatin in colorectal cancer before and after an institutional policy of capecitabine dose reduction

		Univariate analyses			Multivariate analyses
Clinical factors	No. of patients	Risk ratio	95% confidence interval	P	Risk ratio	95% confidence interval	P
Grades 3 and 4 diarrhoea
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	0.88	0.53–1.45	0.61	NA
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	1.65	0.97–2.80	0.07	NA
Gender
Male	239	1			1
Female	161	1.74	1.05–2.90	0.03	1.69	1.01–2.83	0.047
Race
White	363	1
Non-white	37	0.67	0.25–1.77	0.42	NA
Age
<70 years old	262	1
⩾70 years old	138	0.77	0.44–1.32	0.34	NA
Baseline eGFR
>70 ml min^–1	296	1			1
50–70 ml min^–1	93	2.34	1.36–4.03	0.002	2.27	1.31–3.92	0.003
<50 ml min^–1a	11
All grades diarrhoea
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	0.74	0.50–1.10	0.13	NA
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	1.31	0.85–2.03	0.23	NA
Gender
Male	239	1
Female	161	1.23	0.82–1.84	0.32	NA
Race
White	363	1
Non-white	37	0.41	0.20–0.84	0.01	NA
Age
<70 years old	262	1
⩾70 years old	138	1.46	0.96–2.23	0.08	NA
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	1.42	0.88–2.29	0.15	NA
<50 ml min^–1	11	1.08	0.32–3.61	0.90
All grades stomatitis
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	1.09	0.62–1.91	0.77	NA
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	1.88	1.05–3.37	0.03	NA
Gender
Male	239	1
Female	161	1.34	0.76–2.37	0.31	NA
Race
White	363	1
Non-white	37	1.05	0.39–2.81	0.93	NA
Age
<70 years old	262	1
⩾70 years old	138	0.73	0.39–1.35	0.32	NA
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	0.60	0.28–1.28	0.18	NA
<50 ml min^–1	11	1.24	0.26–5.93	0.79
Grades 2–4 hand foot syndrome
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	0.64	0.35–1.16	0.14	NA
Disease extent
Metastatic	284	1			1
(Neo)adjuvant	116	2.62	1.44–4.74	0.002	2.52	1.39–4.59	0.002
Gender
Male	239	1
Female	161	1.01	0.56–1.82	0.98	NA
Race
White	363	1
Non-white	37	0.50	0.22–1.16	0.11	NA
Age
<70 years old	262	1			1
⩾70 years old	138	0.47	0.23–0.94	0.03	0.49	0.24–1.00	0.05
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	1.50	0.79–2.85	0.22	NA
<50 ml min^–1a	11
Grades 3–4 neutropenia
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	0.35	0.14–0.84	0.02	NA
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	1.58	0.70–3.59	0.28	NA
Gender
Male	239	1
Female	161	2.13	0.95–4.76	0.07	NA
Race
White	363	1
Non-white	37	1.30	0.37–4.57	0.68	NA
Age
<70 years old	262	1
⩾70 years old	138	0.68	0.28–1.67	0.40	NA
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	0.74	0.27–2.03	0.56	NA
<50 ml min^–1a	11
All grades neutropenia
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	0.53	0.30–0.93	0.03	NA
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	1.39	0.78–2.48	0.27	NA
Gender
Male	239	1
Female	161	1.47	0.85–2.56	0.17	NA
Race
White	363	1
Non-white	37	0.61	0.26–1.40	0.24	NA
Age
<70 years old	262	1
⩾70 years old	138	0.79	0.43–1.42	0.43	NA
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	0.69	0.34–1.40	0.31	NA
<50 ml min^–1	11	0.52	0.06–4.13	0.53
All grades elevated serum bilirubin
Treatment groups
CAPOX 2000	200	1			1
CAPOX 1700	200	0.44	0.29–0.66	<0.001	0.43	0.29–0.64	<0.001
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	1.02	0.66–1.57	0.92	NA
Gender
Male	239	1			1
Female	161	0.61	0.41–0.91	0.02	0.59	0.39–0.88	0.01
Race
White	363	1
Non-white	37	1.08	0.55–2.12	0.83	NA
Age
<70 years old	262	1
⩾70 years old	138	0.92	0.61–1.39	0.68	NA
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	1.48	0.91–2.32	0.12	NA
<50 ml min^–1	11	0.62	0.18–2.18	0.46
All grades elevated serum ALT
Treatment groups
CAPOX 2000	200	1			1
CAPOX 1700	200	0.60	0.40–0.89	0.01	0.62	0.41–0.93	0.02
Disease extent
Metastatic	284	1			1
(Neo)adjuvant	116	1.77	1.14–2.73	0.01	1.63	1.05–2.54	0.03
Gender
Male	239	1
Female	161	1.43	0.96–2.14	0.08	NA
Race
White	363	1
Non-white	37	0.85	0.43–1.68	0.64	NA
Age
<70 years old	262	1			1
⩾70 years old	138	0.58	0.38–0.88	0.01	0.58	0.38–0.90	0.01
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	0.91	0.57–1.46	0.70	NA
<50 ml min^–1	11	0.92	0.28–3.09	0.90
All grades elevated serum alkaline phosphatase
Treatment groups
CAPOX 2000	200	1
CAPOX 1700	200	1.35	0.91–2.01	0.14	NA
Disease extent
Metastatic	284	1
(Neo)adjuvant	116	0.43	0.27–0.69	<0.001	NA
Gender
Male	239	1
Female	161	1.23	0.82–1.84	0.32	NA
Race
White	363	1
Non-white	37	0.81	0.41–1.63	0.56	NA
Age
<70 years old	262	1
⩾70 years old	138	0.72	0.47–1.10	0.13	NA
Baseline eGFR
>70 ml min^–1	296	1
50–70 ml min^–1	93	0.80	0.50–1.29	0.36	NA
<50 ml min^–1	11	2.32	0.66–8.08	0.19

Abbreviations: ALT=alanine transferase; CAPOX=capecitabine plus oxaliplatin; eGFR=estimated glomerular filtration rate; NA=not applicable.
These factors were non-significant in univariate analyses and, therefore, not entered into multivariate regression models. When less than 2 factors was significant in univariate analyses, no multivariate analysis was performed.
^aBaseline eGFR <50 ml min^–1 had too few events in the category to perform meaningful statistical analyses.

Back to article page

Table 4 Univariate and multivariate analyses of clinical determinants and toxicities

Search

Quick links